top of page

2023 Finalists

Synapse 2023 logos (7 x 4 in).png

AIMA Laboratories

Innovators: Tim Russ, Dr. Jocelyn Wessels, Dr. Lauren Foster

Student: Yianna Suntres


AIMA Laboratories is a Canadian FemTech company that has developed a home test for endometriosis, one of the leading causes of chronic and debilitating pelvic pain. In North America alone there are 8.5M incident cases of pelvic pain in women per year, representing a $2.1B market.


The current path to a diagnosis of endometriosis is costly and unnecessarily long. It takes between 5-12 years and is characterized by multiple physician visits and failed treatments. AIMA’s flagship product will shorten the diagnostic path for endometriosis allowing women clarity, timely access to treatments, and reduced costs to patients and health care providers.

Synapse 2022 logos (7 x 4 in)-8.png

DAZL Innovations

Innovators: Laura Bosch

Student: Somayeh Norouzi Ghazbi

With over 22 years of Nursing experience, DAZL Innovations set out to provide a solution to a problem that had yet to be solved, creating ‘The Lifty’, an all-in-one tool that is easy to use on the various vial sizes available on the market today. Ergonomists have been asking for it, Nurses have been waiting for it, Patients have resorted to desperate measures, Pharmacists and Techs don'tknow what they'e missing, Pharmaceutical Companies could provide it with their products and Medical Supply Companies would do well to stock their shelves with it. Repetative Strain injury is very common in the Healthcare Industry and DAZL Innovations has found a solution to the strain caused by removing IV and Injection caps.

Synapse logo.png


Innovators: Yizhou Chen, Brian Webb

Student: Gavin Yuen

Fat tissue. We all have it – but did you know that it contains cells that can be isolated and repurposed to regenerate other tissue? Well, here at Laetech we are developing novel reconstructive and cosmetic solutions by harnessing the healing power of a patient’s own cells. One problem that affects around half of the US population is that of gingival recession.


The current treatment option is typically using tissue harvested from the roof of the mouth, leading to pain and bleeding, the inability to eat, risk of infection, and the tissue that can be harvested can be insufficient, limiting the scope of care that can be provided. The other alternative is acellular materials, however these lack cells, leading to inferior clinical outcomes whereas we use cells while not having any of the problems associated with autologous grafts. Further, we see this technology having applications in the broader soft tissue repair market, for applications such as replacing fat grafting. We have comprised a team of experts to execute on bringing this product to market and are also being advised by an expert in the isolation of cells from fat tissue as well as two clinicians, providing insight from the end user.

Synapse 2022 logos (7 x 4 in)-3.png


Innovators: Alexander Goel, Joshua Liben

Student: Monisha Divakaran, Aaron Gustafson

Topology Health is developing a suite of products to transform clinical guidelines into actionable person-centric care plans that can be embedded in the clinician workflow. Guidelines allows public health organizations to digitize their guidelines quickly and easily, a no-code user interface. CareMaps is designed to communicate bi- directionally with EMRs so clinicians can easily create care plans for their patients based on the best practice guidelines. These apps will allow clinicians to focus more on their patients, by providing automated, evidence- based recommendations at point of care.

Synapse 2022 logos (7 x 4 in)-2.png


Innovators: Jennifer Polus, Laura Mejia, Jack Elkas, Eric Wang

Student: Yasamin Ghasemi

IRNA offers the first screening and risk-assessment tool capable of detecting and monitoring diabetic retinopathy (DR), a leading cause of blindness worldwide. With a simple blood test and PCR analysis, IRNA has identified biomarkers strongly correlated to DR. This technology facilitates disease detection several years earlier than the current standard assessment, allowing patients to take preventative measures to save their sight. Moreover, tracking biomarker levels over time will inform healthcare providers about the patient response to treatment and guide treatment plans at a patient-specific level.


IRNA aims to be the standard of care screening test that will increase patient compliance and accessibility to frequent DR monitoring, reduce the need to be examined by ophthalmologists, and ultimately save the sight of millions of individuals.

Synapse logo.png

Access Resolve

Innovators: Areeb Khawaja, Mohit Lal, Shivalika Sirohi

Student: Maneesh Gondesi 

AccessResolve is the first health disclosure software which helps employees with disabilities, injuries or illnesses, request workplace accommodations from their employers in a simple, private and compliant manner.

We also enable employers to collect, verify, and manage health disclosures and employee accommodation requests (HIPAA/PIPEDA and SOC2 compliant, of course) with better case management and multiple-stakeholder communication through one platform. We help HR teams step into the digital world of smart accommodations management. Now employers can say goodbye to their lengthy and slow paper-based processes, with our secure platform that guides employees through the process of requesting accommodations and brings the right information to you, faster.

Synapse 2022 logos (7 x 4 in)-4.png

Reya Health

Innovators: Dallas Barnes

Student: Charansakhi Panchal

Reya Health is a digital platform for personalized contraceptive counselling. Reya’s process utilizes smart algorithms, human-centered design and in depth user profiles to match members with birth control methods. Our Birth Control Boundary tracking system supports users in managing any side effects or symptoms.


Reya saves people with ovaries 80% of the time it normally takes to find a birth control option, saves them nearly $1,000 usually spent on options that aren’t the right fit, and provides curated information and follow up support.

Synapse 2022 logos (7 x 4 in)-5.png

Wosler Corp

Innovators: Henry Madubuobi, Marco Gallone, John Paolo Pana

Student: Mann Badami, Zaranaben Pandya

Wosler is a healthcare technology company building a platform of interconnected devices to help improve access to healthcare labour, improve efficiency and reduce cost of healthcare delivery. Wosler's first product is a teleoperated robotic solution that connects a remote ultrasound technologist to patients in rural communities, allowing the technologist to obtain diagnostic ultrasound scans of patients over long distances. Their solution improves access to diagnostic ultrasound for patients in rural communities, reduces cost, and improves efficiency of Sonographers.



Innovators: Catherine Demers, Derya Demirci, Arjun Mehra, Iknoor Sidhu

Student: Jadyn Pereira

Corlibra engages people living with heart failure to safely manage their disease in the home setting. It offers a low cost, simple solution for heart failure self- management specifically adapted to the needs of older individuals.

Synapse 2022 logos (7 x 4 in)-6.png

Canurta Inc

Innovators: Akeem Gardner, Pamela Kisun

Student: Hanxiao Wu

Canurta is a preclinical biotechnology company pioneering the production of safe, effective, and novel polyphenol-rich ingredients and products, which are scientifically proven to target and inhibit inflammation and other mediators of disease at their source, thereby supporting the prevention and recovery across a spectrum of indications for humans and animals in the food, wellness and biopharma sectors.

Synapse 2022 logos (7 x 4 in)-7.png

Wildtech DNA

Innovators: Natalie Schmitt, Keith Liddiard, James Turner

To address the global extinction crisis, WildTechDNA is solving biodiversity loss through conservation rapid diagnostics, at a scale, cost and simplicity never previously possible. Our revolutionary paper-based DNA technology will be inexpensive, easy to use, super-fast and will enable global participation in wildlife monitoring with enormous commercial and conservation benefits. Detecting wildlife from remains is an essential part of conservation, environmental assessment, border security and biodiversity management. However, it is still largely lab- based which is extremely expensive, time-consuming and requires significant scientific expertise.


This prevents most of the world from contributing to conservation efforts. This has huge consequences for illegal wildlife trade enforcement; industrial environmental impact assessment; wildlife pathogen control; agricultural pest control; the monitoring of endangered species and for communities to manage their own environments. So far, we have raised $750,000 from industry, government and philanthropists to fund the research with a world-class team of scientists at McMaster University. We have developed a proof of concept and struck a license agreement with McMaster for exclusive worldwide rights to the IP. Further funding will permit recruitment of additional engineering & research talent to accelerate prototype development as well as conducting a full market assessment to capture the most pressing opportunities.

Synapse logo.png

Rayyan Therapeutics

Innovators: Hasam Madarati

Student: Ibrahim Ilahi

Rayyan Therapeutics is a biopharmaceutical company committed to improving the lives of severely ill patients by combating blood complications associated with severe illnesses.

Rayyan Therapeutics implements the latest laboratory techniques to develop their novel bioproduct drugs that are used for the treatment of various cardiovascular diseases. Founded by the medical scientist, Dr. Hasam Madarati, Rayyan Therapeutics aims to lower the number of deaths associated with cardiovascular diseases from currently being #1 globally to a lower count down the list. Rayyan Therapeutics’ impact is to create a viable treatment that gives hope to severely ill patients by allowing patients to live longer and healthier.

Synapse 2023 logos (7 x 4 in) (11).png

Women's Global Health

Innovators: Leisa Hirtz

Student: Punita Sastry

Over 2 billion people in the world need period products 5-7 days every month for upwards of 40-45 years of their life. This is not a niche market. Currently, this is an annual $5.7bn market growing at a 5.6% CAGR. This market needs disruption and innovation in materials, designs, and distribution models.


WGHI is a for profit social enterprise disrupting the period products market by advancing material science while relying on a user-centered in design approach and environmentally sustainable solutions to improve the lives and health outcomes of the billions globally who experience a monthly period. WGHI has reached the commercial stage selling globally and has established partnerships with International NGOs to meet the development and humanitarian needs of marginalized populations in the global south.

Synapse logo.png

Oakwood Health

Innovators: Jennifer Lowthian

Student: Huma Noor

Over four years of practice, the Oakwood Health Network has refined its, proprietary, multidisciplinary clinical protocols for men& sexual dysfunction. Oakwood Health’s goal is to treat the underlying health issues causing the dysfunction - not just mask the symptoms with drugs - thereby, dramatically improving outcomes. Now Oakwood Health is leveraging technology to take their treatment program to a whole new level. They’ve developed HARDR. - a symptom and activity tracking app for men’s sexual health, available in both app stores. HARDR. will become the first Digital Therapeutic approved by the FDA for men’s sexual dysfunction. Treatment will be powered by a clinical decision support model and the HARDR. Brief - a nighttime wearable under development - will give men unprecedented insights into their own sexual health.

synapse competition vessl prosthetics.png

Vessl Prosthetics Inc.

Innovators: Sydney Robinson, Oleksiy Zaika

Student: Michaela Hughes-Butler

Vessl Prosthetics Inc. has designed an automatically adjusting prosthetic socket for folks with a leg amputation. This socket is designed to make a fulfilling life more comfortable by empowering amputees and their champions to overcome obstacles and realize their full potential. Without the need for prosthetic socks or constant manual socket adjustments, Vessl allows amputees to move freely throughout the day.


Vessl’s patentable technology redistributes pressure around the amputee’s leg to maintain a snug fit. The pain and frustration of dealing with prosthetic sockets often leads amputees to abandon their socket, which is the case for 50% of lower limb amputees. The comfort of Vessl’s socket encourages amputees to keep wearing their prosthesis, which is great news for prosthetists who want to provide helpful solutions to all amputees.

bottom of page